Chinanews.com, Beijing, March 1 (Reporter Li Chun) The National Medical Security Bureau issued a notice on March 1, deploying the centralized procurement and price management of medicines in 2023.

The notice requires that by the end of this year, the cumulative number of national and provincial centralized procurement of medicines in each province will reach 450.

　　The notice pointed out that the coverage of centralized drug procurement should continue to be expanded.

Carry out the eighth batch of centralized drug procurement organized by the state and implement it, and promote the centralized procurement of new batches of drugs in due course.

Provincial-level centralized drug procurement focuses on varieties that have not been included in the national centralized procurement and varieties that have not been reviewed, expand the coverage of centralized procurement from the two dimensions of "filling in the gaps" and "filling in vacancies", and actively explore the "gap" that has not yet been included in the national and provincial centralized procurement "Collected purchases of varieties, encourage price linkage with volume for varieties that have been collected in provinces and have sufficient price competition.

　　The notice pointed out that by the end of 2023, the cumulative number of national and provincial-level collectively-purchased drugs in each province will reach 450, of which provincial-level collectively-purchased drugs should reach 130, and chemical drugs, Chinese patent medicines, and biological drugs should all be covered.

　　The notice also requires exploring and improving the formation mechanism for the initial price of newly approved drugs.

To implement the "Guidelines for the Formation of New Coronary Drug Price Formation (Trial)", six provinces (cities) including Beijing, Tianjin, Hebei, Shanghai, Jiangsu, and Sichuan must do a good job in the acceptance of the initial price, regular evaluation, and dynamic adjustment.

Explore and steadily and orderly expand the coverage of the initial price formation mechanism for newly approved marketed drugs entering the pharmaceutical procurement market, fully encourage innovation and development, guide companies to disclose reasonable pricing, and improve full-cycle price management and supervision.

　　According to the National Medical Security Work Conference on January 12 this year, the average price of the seventh batch of centralized procurement of drugs was reduced by 48%, and the average price of spinal consumables was reduced by 84%.

　　In addition, according to the person in charge of the relevant department of the National Medical Insurance Bureau when answering a reporter's question on February 25, since the establishment of the National Medical Insurance Bureau in 2018, the state has organized a centralized procurement of 294 kinds of drugs, and a batch of high blood pressure, coronary heart disease, diabetes, etc. The average price reduction of medicines for common diseases and chronic diseases in outpatient clinics has exceeded 50%.

Thanks to the sharp price cuts, the proportion of patients using high-quality drugs has increased from 50% before centralized procurement to more than 90%.

　　At the same time, the medical insurance catalog is dynamically adjusted every year according to the principle of "same price, better effect, and better price". A total of 618 new drug reimbursements have been added, of which 341 drugs have been reduced by an average of more than 50% through "soul bargaining", ensuring more patients. I have received new and good medicines that I could not afford or buy in the past.

(over)